Immunovia reports improved test performance of IMMray[TM] PanCan-d in detecting early stage pancreatic cancer in high risk symptomatic patients
Stage I/II pancreatic cancer was detected with a specificity of 92% and a sensitivity of 80% in a clinical study LUND, SWEDEN ― Immunovia today announced improved performance of its blood based IMMray™ PanCan-d biomarker signature together with CA 19-9, in a clinical retrospective study. The study was designed to evaluate detection of early stage pancreatic cancer in high risk patients with non-specific but concerning symptoms. The study data demonstrate that Immunovia’s test now detects pancreatic cancers (all stages) with 92% specificity and 81% sensitivity for this cohort, which is